Artesunate
| File:Artesunate.svg | |
| Clinical data | |
|---|---|
| Routes of administration | oral, IV, IM |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C19H28O8 |
| Molar mass | 384.421 g/mol |
Artesunate (INN) is part of the artemisinin group of drugs that treat malaria. It is a semi-synthetic derivative of artemisinin that is water-soluble and may therefore be given by injection. It is sometimes abbreviated AS.
Uses
Artesunate is used primarily as treatment for malaria; but it has also been shown to be >90% efficacious at reducing egg production in Schistosoma haematobium infection.[1]
Dosing
There are no licensed forms of artesunate available in the U.S. or UK. In the UK, artesunate is available on a named patient basis only.
Intravenous dose of IV artesunate:
- 2.4 mg/kg loading dose over 5 minutes
- 1.2 mg/kg dose 12 hours later
- 1.2 mg/kg once daily after that
Artesunate must always be given with another antimalarial such as mefloquine[2][3] or amodiaquine[4] so as to avoid the development of resistance. The combination of artesunate/amodiaquine has been found to be of equivalent to co-artemether.[5]
Footnotes
- ↑ Boulangier D, Dieng Y, Cisse B; et al. (2007). "Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks". Trans R Soc Trop Med Hyg. 101 (2): 113&ndash, 16. doi:10.1016/j.trstmh.2006.03.003.
- ↑ Looareesuwan S, Viravan C, Vanijanonta S; et al. (1992). "Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria". Lancet. 339 (8797): 821&ndash, 4. PMID 1347854.
- ↑ Nosten F, van Vugt M, Price R; et al. (2000). "Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study". Lancet. 356 (9226): 297&ndash, 302. PMID 11071185.
- ↑ Adjuik M, Agnamey P, Babiker A; et al. (2002). "Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial". Lancet. 359 (9315): 1365&ndash, 72. PMID 11978332.
- ↑ Meremikwu M, Alaribe A, Ejemot R; et al. (2006). "Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial". Malar J. 5: 43. PMID 16704735.
 | This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antimalarial agents
- Terpenes and terpenoids
- Antimicrobial stubs